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Abstract
A better understanding of the relationships between vaccine, immunogenicity and protection from disease would
greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel
tuberculosis vaccine candidate designed to enhance responses induced by BCG. Antigen-specific interferon-γ (IFN-
γ) production is greatly enhanced by MVA85A, however the variability between healthy individuals is extensive. In
this study we have sought to characterize the early changes in gene expression in humans following vaccination with
MVA85A and relate these to long-term immunogenicity. Two days post-vaccination, MVA85A induces a strong
interferon and inflammatory response. Separating volunteers into high and low responders on the basis of T cell
responses to 85A peptides measured during the trial, an expansion of circulating CD4+ CD25+ Foxp3+ cells is seen
in low but not high responders. Additionally, high levels of Toll-like Receptor (TLR) 1 on day of vaccination are
associated with an increased response to antigen 85A. In a classification model, combined expression levels of
TLR1, TICAM2 and CD14 on day of vaccination and CTLA4 and IL2Rα two days post-vaccination can classify high
and low responders with over 80% accuracy. Furthermore, administering MVA85A in mice with anti-TLR2 antibodies
may abrogate high responses, and neutralising antibodies to TLRs 1, 2 or 6 or HMGB1 decrease CXCL2 production
during in vitro stimulation with MVA85A. HMGB1 is released into the supernatant following atimulation with MVA85A
and we propose this signal may be the trigger activating the TLR pathway. This study suggests an important role for
an endogenous ligand in innate sensing of MVA and demonstrates the importance of pattern recognition receptors
and regulatory T cell responses in determining the magnitude of the antigen specific immune response to vaccination
with MVA85A in humans.
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Introduction
Tuberculosis (TB) remains a major global health issue, with
an estimated 8.7 million cases and 1.4 million deaths in 2011
[1]. BCG, the only licensed vaccine against TB, shows only
partial, variable efficacy against pulmonary TB [2–4]. Twelve
candidate vaccines are currently in clinical trials [5] and results
of the first efficacy trial of a new vaccine against
Mycobacterium tuberculosis (M.tb), in which Modified Vaccinia
virus Ankara expressing antigen 85A (MVA85A) was given to
BCG-vaccinated South African infants, have recently been
reported [6]. Although MVA85A did not confer improved
protection to TB compared to BCG alone in this setting, further
analysis of samples collected will provide a valuable
opportunity to investigate the immune basis of protection
against TB.
Efforts to produce T cell inducing vaccines against diseases
such as TB, HIV and malaria, have made use of viral vectors
as antigen delivery systems to enhance the immune response
to the antigen of interest. Vaccine candidates are selected on
the basis of safety, efficacy in preclinical animal disease
models and the ability of the vaccine to induce the secretion of
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interferon-γ (IFN-γ) by antigen-specific CD4+ and CD8+ T-cells
[7–9]. The secretion of cytokines by stimulated cells,
particularly IFN-γ, remains the primary gauge of vaccine-
induced adaptive immune responses in both animals and
humans [10]. IFN-γ is essential for protection against TB and,
although it is not a correlate of protection, it correlates well with
other Th1 functions and is the cytokine that gives the most
robust measure of response to vaccination [11,12]. Therefore it
is of paramount importance to understand the mechanisms by
which different vaccines induce this immune response, as well
as understanding the basis of a protective immune response to
the diseases for which the vaccines are being tested.
Attenuated poxviruses have been widely used in vaccine
development; MVA for example has been tested in clinical trials
against malaria, TB, HIV, influenza and a variety of cancers
[13–18]. There is now interest in determining how MVA initiates
the immune response. The induction of apoptosis by MVA is
well documented [19–21] and recent work has shown that
deletion of the anti-apoptotic gene F1L from the genome of
MVA leads to increased immune responses in mice,
suggesting apoptosis plays an important role in the induction of
immunity to MVA [22]. Additionally, Delaloye et al. have shown
the importance of Toll-Like Receptors 2 and 6 (TLR2-6),
melanoma differentiation-associated gene 5 protein (MDA-5)
and the NALP3 inflammasome in immune sensing of MVA [23],
although no ligand for this association has yet been
characterized. HMGB1, a nuclear protein released during cell
death acts as a danger associated molecular pattern (DAMP)
and can bind to several TLR receptors. It has been implicated
in the immune response to several viruses and has been
proposed as the elusive TLR2 ligand during MVA and vaccinia
infection.
The field of vaccinology has seen, through seminal work
using the yellow fever vaccine YF-17D as a model, that
systems biology can be a powerful tool in identifying the
mechanisms by which an immune response to vaccination
develops [24,25]. In this study we describe the innate immune
response to MVA85A in BCG-vaccinated volunteers in the UK
and use the data to investigate the links between early
changes in gene expression and IFN-γ ELISpot responses
measured at the time of the trial. We are not able to postulate
on the relevance of this to protection, as correlates of
protection remain an elusive goal. However, the ex-vivo IFN-γ
ELISpot is a good measure of vaccine “take” and correlates
with many aspects of Th1 type immunity. It has been used in
multiple studies across different diseases to assess vaccine
immunogenicity, although it is not a correlate of protection in
any of these diseases. In the case of tuberculosis, IFN-γ is also
known to be necessary, though insufficient, for protection.
Understanding the mechanisms underlying the immune
response to vaccination is an important goal that complements
but is separate from studies examining the basis of protective
immunity. MVA85A is designed to augment the T cell
responses induced by BCG through expansion of antigen 85A-
specific T cells, and the immune response to MVA85A has
been studied using the ex-vivo IFN-γ ELISpot in multiple
populations. This work shows the majority of the antigen-
specific response to MVA85A in BCG-vaccinated individuals is
mediated by CD4+ T cells, peaks around 7 days after
vaccination and is maintained at a level above baseline for at
least 6 months [15,26–29]. Here we find that differences in the
regulatory response between volunteers two days after
vaccination are important in determining the magnitude of the
ELISpot response, as is signaling through the TLR2 axis. Low
responders express higher levels of Treg markers including
CTLA4, IL2RΑ and STAT5B pre- and 2 days post-vaccination
and show an expansion of the CD4+ CD25+ Foxp3+ Treg
population in the first week post-vaccination. Additionally,
blocking TLR2 signalling decreases the response to MVA85A
and this is likely mediated by the danger associated molecular
pattern (DAMP) HMGB1, released from dying cells infected by
MVA and signaling through TLR2-6 receptors.
Results
Innate Immune responses to MVA85A
Samples used in this study were taken from a trial of 24
BCG-primed healthy adults from the UK, vaccinated either
intradermally (ID) or intramuscularly (IM) with 1x 108 plaque-
forming units (pfu) MVA85A. Full details of the trial have been
published [30]. Peripheral blood mononuclear cells (PBMC)
from volunteers were cryopreserved on day of vaccination and
at the following timepoints: day 2 and weeks 1, 2, 4 and 12
post-vaccination. IFN-γ ELISpots to antigen 85A peptide pools
were done on fresh PBMC at each time point except day 2
(summary plot shown in Figure S1). In this study unstimulated
PBMC from day of vaccination (day 0) and two and seven days
later (day 2, day 7) were thawed and lysed for gene expression
analysis on Illumina microarrays.
The median IFN-γ ELISpot responses to 85A peptides were
not significantly different between the IM and ID groups at any
time point [30] and, from a filtered list of 22,000 genes, no
genes were differentially expressed between the two groups at
any time point. Both groups were therefore combined for all
subsequent analyses.
Comparing two days after vaccination to baseline, 1100
genes were differentially expressed (false discovery rate
<0.05). Heatmaps showing separation of individual volunteers
using these genes is shown in Figure S2. Analysis of these
genes using Gene Set Enrichment Analysis [31–33] (GSEA)
and the Database for Annotation, Visualisation and Integrated
Discovery [34] (DAVID) showed an enrichment for gene
ontology (GO) terms and gene sets relating to an inflammatory
response, positive regulation of the immune response,
lysosome and apoptosis (Table 1). By day 7, gene expression
had returned almost completely to baseline (Figure 1). The
greatest change in gene expression was seen in the interferon-
induced chemokine CXCL10 (IP-10) with a fold change of 8.5
on day 2 compared to day 0.
We compared this gene signature with changes in gene
expression of PBMC stimulated six hours in vitro with either
media alone, antigen 85A, wild type MVA (MVAwt) or MVA85A.
The PBMC used were from day 0 samples (prior to vaccination
with MVA85A) from the above study. The four volunteers
included were randomly chosen from both low and high
responders to MVA85A (based on previously performed
ELISpot assays). Of the 1100 genes differentially expressed on
Determining the Immune Response to MVA85A
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day 2 in the volunteers, 50% were also differentially expressed
in the cells stimulated in vitro. These genes were enriched for
GO terms including phagocytosis, chemotaxis and the
inflammatory response. The 550 genes upregulated in vivo but
not in vitro were enriched for genes involved in the innate
immune response. A further 4000 genes were differentially
expressed in MVA85A stimulated PBMC compared to the
controls, including genes involved in the lysosome,
inflammation, apoptosis, cytokine-cytokine interactions and
leukocyte migration.
Infection with either MVA85A or MVAwt leads to differential
expression of around 5000 genes compared to the control; of
these, over 3000 were modulated by both MVAs. 176 genes
show significant differential expression when PBMC were
stimulated with MVA85A compared to MVAwt. Around 30
genes were significantly upregulated compared to the negative
media only control when stimulated with any of antigen 85A,
MVA wild type or MVA85A. A list of these is included in table
S1.
High and low responders show differences in gene
expression pre- and post-vaccination
Regulatory T cells increase in low responders following
vaccination.  In order to gain an insight into the mechanisms
associated with differences in ELIspot responses between
volunteers, we divided the 24 volunteers into “high” or “low”
Table 1. Genes upregulated 2 days post vaccination with
MVA85A compared to baseline in healthy volunteers.
Cluster Annotation terma Adjusted
(enrichment score)  p-value
Defense Response (9) Defense response 3.00E-10
 Inflammatory response 9.30E-06
Lysosome (6.52) Lysosome 3.70E-06
NF-κB Signalling (3.27) Positive regulation of I-κB kinase/NF-κBcascade 8.90E-03
Immunoglobulin IgG binding 4.30E-04
Binding (3.25) Immunoglobulin binding 4.40E-04
Immune Response Positive regulation of immune response 3.00E-05
(3.24) Lymphocyte mediated immunity 7.50E-04
 Innate immunity 8.40E-04
Apoptosis (3.19) Regulation of programmed cell death 1.30E-02
 Regulation of apoptosis 1.60E-02
Chemotaxis (2.58) Chemotaxis 2.40E-03
a. Representative annotation terms and their p-value for each annotation cluster.
Figure 1.  Transcriptional response to MVA85A.  Heat map showing changes fold change in gene expression of common genes
2 and 7 days following MVA85A vaccination. The genes are sorted into categories based on DAVID Bioinformatics Database gene
descriptions. The heat map colours show the average expression across the 24 volunteers at each time point (given in days at the
bottom of each column).
doi: 10.1371/journal.pone.0067922.g001
Determining the Immune Response to MVA85A
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e67922
responders based on an area under the curve analysis for IFN-
γ ELISpot responses to 66 overlapping peptides covering
antigen 85A [30]. AUC correlated with immunogenicity at each
time point post-vaccination (r>0.77, p<0.0001 for all
comparisons) and was used to avoid problems associated with
multiple testing. Volunteers with a response greater than the
median AUC were classified as high responders. Additionally,
pre-vaccination responses to purified protein derivative from
M.tb (PPD-T) or to antigen 85A do not correlate with post-
vaccination ELISpot responses to 85A peptides (r=0.16, p=0.43
to PPD-T; r=0.22, p=0.31 to 85A peptide pools), none of the
volunteers had been previously vaccinated with a recombinant
MVA and almost all were too young to have been vaccinated
against smallpox which ceased to be part of the routine
vaccination schedule in the UK in the early 1970s (age range
18-55 years, median 27.5 years).
Two days after vaccination, 176 genes were differentially
expressed between high and low responders. This list of genes
was enriched for GO terms associated with regulation of T-cell
activation and co-stimulation signal (DAVID, fdr<0.05). The
genes contributing to the enrichment of these clusters, which
are more highly expressed in low responders, are shown in
table 2. Although the fold change is low, the enrichment of
genes associated with regulation of T cells suggests this
change is of biological relevance. Furthermore, mRNA of
several genes correlated directly with the IFN-γ ELISpot
responses to vaccination.
To investigate this association further, we then examined
whether increased expression of genes associated with a
regulatory response 2 days after vaccination is reflected in the
regulatory T cell (Treg) compartment. The number of Tregs
(CD4+ CD25+ Foxp3+) in unstimulated PBMC from day of
vaccination and 7 days later were quantified by flow cytometry.
In high responders, the number of Tregs (as a percentage of
CD4+ cells) remained constant pre- and post vaccination,
however in low responders it increased between day 0 and day
7 (Figure 2a, p = 0.009). The expression of STAT5B mRNA on
day 0 correlated with the percentage of Tregs seen in PBMC
on day 7 (p=0.41, r=0.047). There was also a weak association
between CTLA4 mRNA on day 2 and percentage of Tregs
seen in PBMC on day 7 although the correlation did not reach
significance (Figure 2b, rs = 0.39p=0.058).
TLR1, TICAM2 and CD14 are more highly expressed in
high responders on day of vaccination.  On day of
vaccination (day 0), 400 genes were differentially expressed
between high and low responders however these were not
enriched for any GO terms. We analysed these genes using
pamR (prediction analysis for microarray) [35] and identified
nine genes that could classify the 24 volunteers as high or low
responders with a cross validation accuracy of 87% (Figure 3a;
GAPT: GRB2-binding adaptor protein, transmembrane;
ZMYND15: zinc finger, MYND-type containing 15; MGST1:
microsomal glutathione S-transferase 1; CD300LF: CD300
molecule-like family member f; NPL: N-acetylneuraminate
pyruvate lyase; FPR3: formyl peptide receptor 3; TLR1: toll-like
receptor 1 and TICAM2: toll-like receptor adaptor molecule 2).
To determine the reproducibility of this finding, we used 10
samples from a previous trial in which the volunteers were
vaccinated ID with an equivalent dose of MVA85A [36]. We
measured the expression of the nine genes by qPCR and
again classified the volunteers as high or low responders
based on the median AUC value for their ELISpot responses
(in both trials, the medians were 41000 spots. time/million
PBMC). We then performed a univariate logistic regression for
each gene and, as the sample size was small, retained all
genes with moderate discriminatory power (p≤0.2).
The three genes retained were: TLR1, CD14 and TICAM2.
While CD14 expression correlates with AUC (p=0.006, r=0.3),
monocyte levels (as determined by full blood counts) do not
(p=0.9, r=0) and therefore CD14 expression is not simply a
reflection of the number of circulating monocytes. Using linear
discriminant analysis (LDA), the mRNA levels of TLR1,
TICAM2 and CD14 on day of vaccination could classify
individuals as high or low responders with a cross-validation
accuracy of 80%. Doing the same LDA analysis on the original
24 samples, using microarray values for the expression levels
of the same three genes, the cross validation accuracy was
79% (Figure 3b).
Although no discriminatory gene set was found based on
gene expression 2 days after vaccination, adding CTLA4 and
IL2RΑ (CD25) to the LDA model developed with the three
innate sensor genes refined the model and increased its cross
validation accuracy to 88% (Figure 3c, d). Unfortunately we
were not able to validate this finding on the second trial, as day
2 samples were not available.
TLR1 expression on day of vaccination correlates with
ELISpot responses.  For each of the three genes, we also
performed linear regression analysis with ELISpot AUC values
for individual volunteers. This analysis is not possible with a
high number of genes but could be informative when thinking of
the mechanisms linking vaccine sensing and immunogenicity.
The levels of TLR1 mRNA in both trials correlated with AUC
(Figure 4a; p < 0.05, Spearman’s r=0.70, p<0.01, Spearman’s
r=0.55 respectively).
We examined the original 24 samples by flow cytometry,
gating on live cells, and looked at mean fluorescence intensity
of TLR1. TLR1 is ubiquitously expressed and, as the original
microarray analysis was done on PBMC, we did not narrow
down the population further using other markers. There was a
correlation between the level of TLR1 expression on day of
vaccination and AUC, although the relationship was weaker at
Table 2. Differentially expressed genes between high and
low responders, two days after vaccination.
SYMBOL Description Fold Change adj. p-value
CTLA4 Cytotoxic T lymphocyte antigen 4 1.77 0.037
CD5 T cell surface antigen 1.62 0.032
IL2RΑ (CD25) IL2 receptor, α subunit 1.58 0.043
TRAT1 TCR associated adaptor molecule 1.48 0.03
STAT5B T cell transcription factor 1.48 0.043
CD28 co-stimulatory molecule 1.43 0.038
CD3D T-cell receptor, δ subunit 1.41 0.025
ITK IL-2 inducible T cell kinase 1.4 0.048
CD2 T cell surface antigen 1.34 0.047
DNAJA3 DnaJ (Hsp40) homologue 1.3 0.034
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the protein level compared to the mRNA (Figure 4b,c; p<0.05,
Spearman’s r=0.45).
Blocking signalling through the TLR2 axis reduces
responses to MVA85A in vitro
Following analysis of the microarray data, we sought to
examine the relationship between the innate response to
MVA85A and TLR1 in vitro. TLR1 and TLR6 are located in
tandem on chromosome 4 and evolved following a gene
duplication event. The two receptors share extensive homology
and both signal as a heterodimer with TLR2 [37]. Contrary to
TLR1, TLR6 is not ubiquitously expressed [38] and this may
make it less likely to be identified in a microarray analysis of
circulating PBMC. Due to this, and previous results showing
that MVA signals through TLR2-6 rather than TLR1-2, we
investigated all three receptors in the TLR2 family. Blocking
signaling through all three TLRs during in vitro stimulation of
Figure 2.  Low responders make a stronger regulatory response to vaccination with MVA85A.  To further explore the
relationship between Treg marlers and IFN-γ ELISpot response identified through the microarray, flow cytometry of Treg markers
was done of cells from the same volunteers taken on day of vaccination (day 0) and 1 week later (day 7). - A. mRNA levels as
measured by microarray for several Treg markers show an inverse correlation with the IFN-γ ELISpot response. B. The Treg
population (CD4+ CD25+ Foxp3+) is increased in low but not high responders during the first week following vaccination (paired t-
test, p=0.009) C. STAT5B expression on day 0 correlates with frequency of Tregs (CD25+ Foxp3+, % CD4+) and there is a trend
between expression of CTLA4 on day 2 and Tregs on day 7. Treg absolute counts: mean: 1687, median: 1631, interquartile range:
740-2882.
doi: 10.1371/journal.pone.0067922.g002
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Figure 3.  Expression of genes on day of vaccination and 2 days later can classify high and low responders.  Cohorts:
TB022: 24 volunteers used in the original microarray analysis. TB009: 10 volunteers from a previous trial of MVA85A who received
an equivalent dose used in the qPCR validation. A. Exploratory list of 9 genes obtained from the prediction analysis done on the
microarray data from TB022 B. Probability plots of linear discriminant analysis classification outcomes of high and low responders in
trials TB022 and TB009 from expression of TLR1, TICAM2 and CD14 on day of vaccination. C. Probability plot of LDA classification
outcome of TB022 volunteers when CTLA4 and IL2RΑ expression on day 2 are added to the model (Other genes, eg CD5 and
STAT5B were removed as they did not add predictive value to the model due to co-linearity with other genes). D. Hypothesis
resulting from LDA analyses.
doi: 10.1371/journal.pone.0067922.g003
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PBMC with MVA85A reduces expression of CXCL2 in
response to the virus (Figure 5a). MVA leads to activation of
multiple innate signaling pathways. This data is consistent with
previous results showing that activation of the NFκB pathway in
response to MVA stimulation (in this case MVA85A) is
dependent on signaling through TLR2. In contrast to previous
data, we did not find a difference between blocking signaling
through TLR1 or TLR6, however we found the effect of TLR1
blocking to be donor dependent (i.e. in some donors, TLR1
neutralising antibodies consistently decreased CXCL2
expression in response to MVA85A stimulation whereas with
other donors there was no effect, data not shown).
HMGB1 is secreted following MVA85A and neutralizing
it reduces the response to MVA
The nuclear protein HMGB1 is released under some
conditions of cell death and can signal as a DAMP through
Figure 4.  TLR1 levels on day of vaccination correlate with immunogenicity.  A. Levels of TLR1 mRNA correlated with long
term immunogenicity to MVA85A in TB022 (Spearman’s rank correlation). B. Levels of TLR1 mRNA correlated with long term
immunogenicity to MVA85A in TB009 (Spearman’s rank correlation). C. Surface expression of TLR1 varies greatly between
individuals. D. Median fluorescence intensity (MFI) of surface TLR1 on all live cells in unstimulated day 0 samples correlates with
immunogenicity (TB022).
doi: 10.1371/journal.pone.0067922.g004
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TLR2 [39–42]. It has been reported to be important in signaling
following poxvirus infection [43,44] so we investigated whether
it could be playing a role in this setting. HMGB1 was not one of
the genes identified in the microarray, however its mechanism
of action in this setting is due to a change in cellular location (ie
from the nucleus of dying cells to the extracellular space where
its presence acts as a danger signal) rather than an increase in
transcription so this is not necessarily unexpected. HMGB1 is
detectable by western blot in the supernatant of infected cells 4
and 6 hours post infection but not in the supernatant of
uninfected cells after 6 hours. Furthermore, anti-HMGB1
antibodies also reduce the production of CXCL2 in cells
stimulated with MVA85A (Figure 5b, c).
Figure 5.  Toll-like receptors and HMGB1 in the innate response to MVA85A.  A. Incubating PBMC with TLR blocking
antibodies decreases CXCL2 production in response to MVA85A (Mann-Witney test for all 4 comparisons 0.01<p<0.05). B. Anti-
HMGB1 also reduces CXCL2 production in response to MVA85A stimulation (Wilcoxon paired test, p<0.05). C. Western blot
showing HMGB1 is released into the supernatant of MVA85A stimulated but not unstimulated cells. D. Mixing anti-TLR2 to MVA85A
when vaccinating mice reduces the spread of responses (F-test, p<0.05) but not the mean (student’s t-test, p=0.18 MVA vs anti-
TLR2, p=0.12 MVA85A vs isotype control).
doi: 10.1371/journal.pone.0067922.g005
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Blocking signalling through the TLR2 axis reduces
responses to MVA85A in vivo
Mice were vaccinated with 5 x 105 pfu MVA85A with or
without a TLR2 neutralising antibody or an isotype control.
Mice were culled seven days later and responses to the
antigen 85A insert determined by IFN-γ ELISpot on splenocyte
responses to a 66 peptide pool. The results show a decrease in
high responses to antigen 85A. The mean responses are
slightly lower than in the control and isotype groups however
the main difference seems to be in the spread of the
distribution, particularly in the lack of high responses in the
group receiving anti-TLR2 antibodies with the vaccine (Figure
5d; all three groups are normally distributed by the D’Agostino
and Pearson normality test, F test for differences in variance:
p=0.04 between MVA85A and anti-TLR2, p=0.02 between anti-
TLR2 and isotype groups).
Discussion
As efforts to find a successful vaccine against TB, malaria,
HIV and other diseases continue to grow, there is a need to
develop our understanding of the molecular and immunological
events associated with different methods of vaccination. A
number of characteristics make recombinant poxviruses
attractive targets for vector development and there have now
been many vaccine trials conducted with recombinant
poxviruses expressing different antigens. These vaccines
consistently induce strong Th1 responses [14,16,45] however
the magnitude of these responses varies between individuals
and populations with potential impact for the applicability of
early clinical studies. For example, lack of enhanced efficacy in
a recent trial in BCG-vaccinated infants may link to lower
immunogenicity in this population compared to UK adults
[6,46]. An understanding of the processes linking recognition of
the vector and early immune events at a molecular level to the
vaccine-elicited immune response will aid the future
development of these vaccines.
In this study we begin by describing the transcriptional
changes that occur in vivo following vaccination of healthy
BCG-vaccinated UK adults with MVA85A. Expression levels of
a huge number of genes are modulated by MVA85A and
changes are strongly apparent in circulating PBMC two days
after vaccination, reflecting a systemic activation of
inflammatory pathways. The peak adaptive response to
vaccination with MVA85A is relatively early at 7 days and,
consistent with this, the changes in gene expression following
vaccination with MVA85A are both early and transient. This is
in contrast to data published on the yellow fever vaccine, which
shows a peak in expression of innate genes 7 days post-
vaccination. This difference likely reflects the non-replicating
nature of the MVA vector [25,47]. The much earlier peak in
innate signaling is likely to impact the development of the
adaptive immune response. The changes in gene expression
observed in the PBMC reflect the extent of the adjuvanting
properties of the MVA vector as few, if any, circulating
leukocytes will have been directly exposed to MVA.
Differences between differentially expressed sets of genes in
the in vivo and in vitro experiments may have multiple causes.
Timing will account for some differences. Additionally, contrary
to circulating PBMC, most cells in the in vitro experiment will
have been either infected with MVA or in close contact with
infected cells. Changes in processes including the lysosome,
apoptosis, and phagocytosis, all of which are known to be
important during infection with MVA [23,47,48], are therefore
visible. A large overlap in genes modulated by both MVAwt and
MVA85A in stimulated PBMC suggests the findings of this
study will be applicable to other uses of MVA as a boosting
vector.
Poxviruses have been selected as vaccine vectors for their
ability to accommodate large inserts into their genomes
(>25kb) and to induce potent T cell responses [44]. However
the molecular mechanisms by which these responses are
elicited, and the reason for the range of immunogenicity, are
still not well understood. Heterogeneity in responses to
vaccination is common and the reasons underlying it are
specific to each vaccine. For example a polymorphism in TLR1
is associated with lower antibody levels in response to
vaccination against Borrelia burgdorferi (genotyping of the
reported SNP was performed in these volunteers but was not
related to immunogenicity or mRNA levels, data not shown)
[49]. More recently, Querec et al. demonstrated that a gene
signature including the transcription initiation factor EIF2AK4
could predict antigen-specific CD8+ T cell responses to the
yellow fever vaccine. This kinase, also known as GCN2, can
activate the integrated stress response secondary to arginine
depletion and the authors speculate that induction of the stress
response directs the adaptive response to vaccination in this
setting [25].
Two days after vaccination, low responders had higher
expression of genes associated with the regulatory response,
notably CTLA4, IL2RΑ (CD25) and STAT5B. CTLA4 is found
on the surface of T cells and mediates inhibitory signals
through binding of CD80 and CD86 on antigen presenting cells
(APCs), IL2RΑ is a surface marker of Tregs and STAT5B
regulates transcription of a number of Treg associated genes.
Patients with a deficiency in the STAT5B pathway have been
shown to have fewer circulating Tregs. Expression of these
genes correlated with decreased responses to MVA85A.
Furthermore, these early changes in gene expression reflected
a difference in the expansion of Tregs, which was seen in low
but not high volunteers. Low expression of STAT5B on day 0
and CTLA4 on day 2 both showed a weak correlation with Treg
numbers on day 7. These associations suggest that Tregs are
an important contributor in determining the magnitude of the
IFN-γ ELISpot response. Although drawing firm conclusions
from small data sets is difficult, these preliminary data warrant
further investigation into the role of Tregs and Treg markers in
response to vaccination with MVA vectored vaccines. This
increase in regulatory activity in low responders is consistent
with previous work showing that high levels of TGF-β in the
serum on day of vaccination with MVA85A resulted in lower
IFN-γ ELISpot responses post-vaccination [50]. Although we
saw a difference in the Treg population, we do not know what
factors are causing a stronger regulatory response to develop
in some vaccinees but not others, or whether vaccination is
simply accentuating differences in the Treg compartment that
were already present in volunteers. Both genetic and
environmental factors are likely to influence the regulatory
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response to MVA85A, which may be specific to the vaccine or
a reflection of the immune status of an individual at the time of
vaccination. Additionally, we cannot exclude the possibility that
expression of TLRs and regulatory receptors may be linked.
Expression levels of three genes on day of vaccination, all
involved in pattern recognition and triggering of an innate
signal, allow good classification of high and low responders in
two different trials. This suggests that the number of certain
pattern recognition receptors (PRRs) at the time of vaccination
strongly influences the number of antigen-specific IFN-γ
secreting cells that develop. In particular, TLR1 expression
correlates with immunogenicity, leading us to hypothesize that
MVA signaling through the TLR1-2-6 axis is important in the
development of the adaptive immune response. In vitro work
shows that innate signaling through NF-κB is decreased
following stimulation with MVA85A in the presence of
neutralizing antibodies to TLR1, 2 or 6. Additionally, blocking
signaling through these receptors by including a TLR2 antibody
with the MVA85A vaccine administered to mice also appears to
diminish high ELISpot responses, although the mean response
to vaccination is not significantly lower. This suggests that the
strength of the signal through TLR2 is affecting the magnitude
of the adaptive response that develops but it is neither the only
innate mechanism by which MVA is sensed nor is it the sole
determinant of antigen specific immunity. Poxviruses have
been infecting human populations for millennia and elicit a
plethora of innate responses [44]. The strength and versatility
of the innate response to MVA is evident from the array data
and has been shown by other groups [51]; although it is
dominated by interferon responses, different aspects of the
innate response may be playing different roles in directing the
adaptive response to vaccination.
Although MVA and its parent strain vaccinia have previously
been shown to signal through TLR2 [23,52], no viral ligand for
this interaction has been proposed and TLR2 is better known
for binding to molecular patterns of bacterial and fungal origin
[53]. HMGB1 has been suggested as a ligand for TLR2 in
signaling following infection with different poxviruses as it is
released during cell death and many attenuated strains of
vaccinia virus cause widespread cell death, having lost
molecules which inhibit apoptosis in the parent strain [43,54].
We show that HMGB1 is released from cells following MVA85A
stimulation and that antibodies to HMGB1 can decrease
CXCL2 expression in these stimulations. These data suggest
that response to cell death following vaccination with MVA85A,
in particular through the release of HMGB1 and its interaction
with TLR2, is a strong determinant of the magnitude of the
adaptive immune response that develops. Consistent with this,
a recent study by Perdiguero and colleagues has shown that
deletion of the anti-apoptotic gene F1L from the candidate HIV
vaccine MVA-C enhances its immunogenicity in mice [22].
Furthermore, it has been shown that, in dendritic cell cultures
infected with MVA, the majority of the functional response and
maturation was observed in non-infected bystander cells [20].
This leads us to the model that vaccination with MVA85A
causes death of infected cells and the release HMGB1, which
then signals through TLR2 and either TLR1 or TLR6. The
magnitude of this signal, which in humans may be determined
by the considerable range of TLR expression seen on the
surface of PBMC from healthy adults, is one of the factors
determining the magnitude of the developing adaptive
response to the vaccine. HMGB1 can under some conditions
also activate TLR4 [42], which signals through the adaptor
protein TICAM2. Therefore it is possible that the two pathways
have different relative contributions in different individuals and
thus including both can refine classification models. As with the
case of the yellow fever vaccine, a danger-associated signal
resulting from cellular stress or damage appears to be a strong
determinant of the magnitude of the adaptive response.
In summary, we find that low responses to vaccination with
MVA85A are associated with lower expression of TLR1 on day
of vaccination and a regulatory response leading to expansion
of Tregs over the seven days following vaccination. This study
highlights features of the immune response that are important
in determining the number of antigen-specific IFN-γ secreting
cells in response to vaccination with MVA85A boosting BCG-
induced responses. It is possible that the relative influence of
different innate mechanisms on the development of the
adaptive response may change when MVA is used with a
different priming vaccine or if another measure of
immunogenicity is investigated. However this study shows
mechanisms important in humans in determining the often-
measured immune parameter of antigen-specific IFN-γ
secreting cells, and furthers the understanding of the
relationship between early innate responses to vaccination and
how these relate to the facets of the adaptive immune
response that are being measured. Generating hypotheses
from a human trial ensures the mechanisms being studied are
relevant to the target species for vaccination, although further
work will be needed to establish whether these results are
applicable to other populations. Determining the importance of
these mechanisms in the development of the vaccine-induced
immune response in infants and HIV-infected adults in TB
endemic countries will be of particular importance. Hopefully
studies like these, combined with data on correlates of
protective immunity emerging from recent efficacy trials, can
inform the design of future vaccines.
Materials and Methods
Clinical trials
PBMC used in these studies were from volunteers from 2
clinical trials in which volunteers (aged 18-55) were recruited
on the basis of prior BCG vaccination. The trials were
registered on the clinical trials database (ClinicalTrials.gov IDs:
NCT01181856 (TB022) and NCT00465465 (TB009)).
Volunteers received a dose of 1 x 108 pfu MVA85A injected
either intradermally or intramuscularly. Both trials were fully
approved by the ethical and regulatory agencies (Oxfordshire
REC A and the Medicines and Healthcare products Regulatory
Agency). Full written consent was obtained from each subject
prior to enrollment in the trial, which was conducted according
to the principles of the Declaration of Helsinki and in
accordance with Good Clinical Practice (GCP). Storage of
samples for exploratory immunological analyses was fully
ethically approved.
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Cryopreservation of PBMC and ex-vivo IFN-γ ELISpot
PBMC from vaccinated subjects were cryopreserved in liquid
nitrogen at time of acquisition as previously described [55].
IFN-γ ELISpots were performed ex-vivo at screening and
weeks 1,2,4,12, and 24 post-vaccination as previously
described [29]. The safety and primary immunological
outcomes of these trials have been published elsewhere
[30,36].
Cell thawing, in vitro stimulation and RNA extraction
Frozen PBMC were thawed washed and counted as
previously described [55]. 2x106 cells were lysed in 350µL RLT
buffer containing 10µL/mL β-mercaptoethanol and stored at
-20oC. The RNA was extracted using the Qiagen RNeasy mini
kit according to manufacturer’s instructions and stored at
-80oC.
For the in vitro stimulation experiments, cells were rested 2
hours in benzonase endonuclease (Novagen), washed, then
2x106 cells for each condition were stimulated for 6hrs with
either media alone (10% FBS (Fetal Bovine Serum; Biosera
Ltd.), 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL
streptomycin in RPMI 1640) or media containing antigen85A
(20 µg/mL), wild type MVA or MVA85A both at an MOI of 1
(MOI of 5 for the blocking experiments). The stimulation
volume was 200 µL. In the TLR blocking experiments, 20µg/mL
of the following antibodies were added to the medium as
indicated. All antibodies were neutralizing polyclonal rat IgG
from ivivogen; TLR1 (pab-hstlr1), TLR2 (pab-hstlr2), TLR6
(pab-hstlr1) and isotype control (pab-sctr). The cells were then
lysed and frozen in 350µL RLT buffer containing 10µL/mL β-
mercaptoethanol and RNA extracted as above.
Gene Expression Analysis
The RNA was amplified using the Illumina Totalprep RNA
Amplification Kit (Ambion), according to manufacturer’s
instruction. The median yield after amplification was 6.6 µg
RNA (range 4-15.3µg). The quality of the RNA was checked on
an Agilent bioanalyser following extraction (median RNA
Integrity Number (RIN) of 8.6: range 7.4-9.7) and again
following amplification. Amplified RNA (750ng per array) was
hybridized to the Illumina HumanHT-12 version 4 expression
beadchip according to manufacturer’s instructions. Arrays were
scanned with an Illumina bead array reader confocal scanner.
Quantitative PCR
RNA was reverse transcribed to cDNA using oligo-dT and
the Omniscript reverse transcription kit (Qiagen). cDNA was
stored at -20°C until qPCR was performed, using the Roche
LightCycler® 480 and Quantitect mastermix (Qiagen).
Quantified, purified and diluted PCR product was used to
generate internal standard curves for each primer pair (table 3).
Cycle number values were converted to copy number using
these curves. Cycling conditions consisted of an initial
activation step of 15 minute at 95°C followed by 45 cycles of 15
seconds at 94°C, 20 seconds at 60 °C and 15 seconds at 72
°C, for each primer pair.
Flow cytometry
Anti-human antibodies (PE anti-TLR1, PB anti-CD19, AF700
anti-CD3, APC anti-CD4, APC-AF700 anti-CD8, AF647 anti-
Foxp3, APC-Cy7 anti-CD25, PE anti-CTLA4) were purchased
from Biolegend and QDot655 anti-CD14 and the ViViD Live/
Dead cell stain from Invitrogen. A FACSCalibur (Becton
Dickinson) was used for flow cytometry event collection and
events were analysed using FlowJo (Tree Star Inc.). The gating
strategy is shown in Figure S3.
Western blot
Stimulations with MVAwt were stopped after 0 minutes, 30
minutes and 1, 2, 4 and 6 hours and the supernatants stored at
-20 oC. They were then thawed and concentrated for 20
minutes in Amicon Ultra-0.5 10kDA filters (Millipore UK)
according to the manufacturer’s instructions. The supernatant
was mixed 1:1 with loading dye, run 1 hour at 100 Volts on a
4-20% precise protein gel (Thermo Scientific Pierce) and
transferred to a membrane (Trans-Blot Turbo Transfer Pack,
Bio-Rad Laboratories Ltd) by Turbo blotting for 7 minutes. The
membrane was incubated sequentially for 1 hour with PBS with
3% BSA alone, primary antibody (mouse anti-human HMGB1,
Biolegend, UK) and finally secondary antibody (Alkaline
Phosphatase-AffiniPure Donkey Anti-Mouse IgG, Stratech
Scientific Limited). The membrane was washed and developed.
Table 3. Primer sequences for quantitative PCR.
Gene Forward primer Reverse primer
GAPT CCTGCCAAACTTATCCTTCCTTCACAGC ATGCGGGTTTGGAGTGATTCAGGA
ZMYND15 TCCTGAATCACTCCAAACCCGCAT GTGATGTTCTAGGCATTTGGGCAG
MGST1 TTGGCCTCCTGTATTCCTTGAGTG TGGTAGATCCGTGCTCCGACAAAT
NPL CAACTCTCAGTCATTCATTTCACAGAT AGGATTAGGAACCAGAGACCGAGA
CD300LF AAGAGGCCAGAAGGTCAAAGAGGT TTTCAATGGGCTCAAGTCAAGGCG
FPR3 TGAGTCATTCCAGGATGAGTGGCT ACACCCACAGTGGCCTCATTATCT
TLR1 AACCCATTCCGCAGTACTCCATTC ATGGCTGCCCTTAAGTTAGCCCAA
TICAM2 AGTACCGGGATCTGCACACATCTT AGGCTTGACTTACTTGCATGCTCC
CD14 AACTCCCTCAATCTGTCGTTCGCT TTCAGTCTGTTGCAGCTGAGATCG
TLR6 ATATGGCTTCATGGCAGCAAGGGA AATATGATTCACAGGGCACTCCGAGG
CXCL2 TAGCCACACTCAAGAATGGGCAGA ACAGCCACCAATAAGCTTCCTCCT
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Unfortunately a good loading control for western blots using
cell supernatants has not been published and is not routinely
used [40,56].
Mouse experiments
All experiments were done on 6- to 8-wk-old female BALB/c
mice (Harlan Orlac). All procedures were carried out under the
terms of the UK Animals (Scientific Procedures) Act Home
Office Project Licence (UK Home Office PPL 30/2412) and
were approved by the University of Oxford Animal Care and
Ethical Review Committee. Mice were vaccinated intradermally
(i.d.) in each ear (25 µl/ear). Groups of 5 mice were vaccinated
with 5×105 plaque forming units (pfu) of MVA85A (MVA) in PBS
alone or also containing 20µg of anti-TLR2 antibody (MAB
1530, R&D Systems) or an isotype control. The mice were
culled 7 days later and ammonium chloride lysis buffer (ACK)-
treated splenocytes used in an IFN-γ ELISpot assay. The cells
were stimulated with either media alone, PHA and PMA or
antigen 85A 66 peptide pool as previously described [57].
Microarray Data Processing
Raw illumina probe data was exported from Beadstudio and
screened for quality. Gene expression data was analysed using
the bioconductor platform in R [58]. Genes not expressed
above background levels in any sample were removed
(p<0.05). In limma [59,60], background correction and quantile
normalization was done using the neqc function [61]. Probes
with an interquartile intensity range <0.3 (log2 transformed)
across all samples were filtered using bioconductor’s genefilter
package. The remaining 22000 probes were retained for
differential expression analysis. Using limma, fold-change in
expression between predefined groups was estimated. p-
values from the resulting comparison were adjusted for multiple
testing according to the method of Benjamini and Hochberg set
to 0.05. Array quality was accounted for in the analysis using
limma’s arrayWeights function, which estimates the relative
reliability of each array by measuring how well its expression
values follow the linear model.
Pathway analysis was performed using two web-based tools;
DAVID (Database for Annotation, Visualisation and Integrated
Discovery) and GSEA (Gene Set Enrichment Analysis). These
two methods analyse upregulated genes by grouping them into
pathways and transcriptional modules, which allows greater
analytical power and biological insight. Whilst DAVID relies on
published pathways and gene ontology databases to generate
results, GSEA uses published gene sets. In GSEA, lists of
differentially expressed genes were ranked by fold-change in
expression and used in the preranked analysis. We
systematically tested gene sets from the Molecular signature
Database (MsigDB, http://www.broad.mit.edu/gsea/msigdb) C2
collection collected from various sources such as online
pathway databases and publications in PubMed.
To see whether any genes could predict the immune
response to vaccination, we used a nearest shrunken centroid
method in the R package prediction analysis for microarrays
(pamR). The gene list was first filtered to exclude any gene
whose fold change in gene expression was less than 1.4 (20.5)
in at least 40% of volunteers following vaccination, leaving
approximately 5000 genes. Through an interactive interface,
pamR uses a nearest shrunken centroid method to make an
estimate of cross-validation error for each threshold value and
the optimal threshold yielding the lowest cross-validation error
rate chosen. In this study, this resulted in the selection of 9
genes that could classify the vaccines with a maximal efficacy
of 87%. These were taken forwarded for a validation study
using quantitative PCR.
Statistical analyses
To obtain a single measure of immunogenicity, an area
under the curve analysis (AUC) was done in Prism on ELISpot
immunogenicity data for each volunteer. The time points used
were screening (as the baseline) and 1, 2, 4, 12 and 24 weeks
post-vaccination. Volunteers were classed as “high” or “low”
responders based on whether their ELISpot AUC was above or
below the median (41,000 SFU.weeks/106 cells in both trials).
For the real-time RT-PCR data the mean Ct value of
duplicate capillaries was converted to copy number using
internal standard curves generated from purified and quantified
PCR product. Expression levels for each gene were normalised
by dividing copy number of gene by copy number of the
housekeeping gene HPRT. For TLR1, normalized copy number
was correlated to AUC using Spearman’s rank test in Prism.
This test was also used to correlate AUC to TLR1 levels
measured by flow cytometry. Also using GraphPad Prism, the
student’s t-test was used to compare means in the in vitro
stimulations, D’Agostino and Pearson’s test to check for
normality and the F-test to compare variances.
Univariate logistic regression was done in R for each gene in
the validation trial. Those genes with moderate discriminatory
power (p≤0.2) were further analysed using linear discriminant
analysis (LDA) in the R package MASS. LDA discriminates
between two or more classes by maximizing the ratio between
class variance and within class variance using a linear
combination of input variables. Once a model is built, Euclidean
distance is used to classify new samples. The LDA
Classification error was assessed using cross validation.
Accession code
Gene Expression omnibus, microarray data: GSE40719.
Supporting Information
Figure S1.  Boxplot showing IFN-γ ELISpot responses to
antigen 85A peptide pools for the two trials from which
samples in this study were taken. TB022 (open bars) and
TB009 (shaded bars). Plot shows median, interquartile
range and maximum and minimum.  Primary data has been
published:
TB022:
Meyer J, Harris S, Satti I, Poulton ID, Poyntz HC, et al. (2013)
Comparing the safety and immunogenicity of a candidate TB
vaccine MVA85A administered by intramuscular and
intradermal delivery. Vaccine 31: 1026–1033.
TB009:
Pathan A, Minassian AM, Sander CR, Rowland R, Porter DW,
et al. (2012) Effect of vaccine dose on the safety and
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immunogenicity of a candidate TB vaccine, MVA85A, in BCG
vaccinated UK adults. Vaccine: 1–9.
(EPS)
Figure S2.  Heatmap of individual samples using a list of
differentially expressed genes between days 0 and 2 (a. fdr
corrected p<0.05; b. fdr corrected p<0.0005). Function
uses complete linkage clustering of euclidean
distance.  (TIFF)
Figure S3.  Samples for flow cytometry analysis of Tregs
or TLR1 were gated as shown above for steps 1-3: cells
(FSC-A, SSC-A), singlets (FSC-A, FSC-H). Dump: ViVid and
CD19 on Pacific blue. For Treg analysis cells were selected
as shown: CD14-, CD3+, CD4+ and CD25+ Foxp3+.  For
analysis of TLR1 expression, MFI of TLR1-PE was calculated
after gating out of ViVid dead and CD19+ cells as shown in
Figure 3.
(EPS)
Table S1.  Differentially expressed genes between in vitro
stimulated PBMC.  Differentially expressed genes between
MVA85A (up in bold) and MVA wild type (up in italics)
stimulated PBMC. Fdr<0.05.
Venn diagram showing overlap of deifferentially expressed
genes between stimulation with antigen 85A, MVAwt or
MVA85A, all compared to negative control (media only).
List of genes differentially expressed by all three stimulations
compared to controls.
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